Peptide Therapy vs TRT: Which Is Right for You?

Testosterone replacement therapy and peptide therapy get lumped together constantly in men's health and longevity conversations, but they work on entirely different principles and sit in very different regulatory positions in Ireland. TRT replaces a hormone directly: if bloodwork shows your testosterone is genuinely low, TRT puts measurable testosterone back into your bloodstream, typically as a gel, cream, or injection, under a doctor's ongoing supervision.

Peptide therapy, as commonly discussed in this space, usually means a different family of substances entirely: short chains of amino acids such as BPC-157, marketed for tissue and gut healing, or CJC-1295 and Ipamorelin, marketed as growth hormone secretagogues intended to prompt your pituitary gland to release more of its own growth hormone rather than replacing a hormone directly. The theory is appealing, working with the body's own signalling systems rather than overriding them, but the regulatory and evidence picture is a great deal thinner than for TRT.

This article compares the two honestly: what each is licensed for, what the evidence actually supports, what they cost, and the practical and legal considerations that should shape a decision made with a doctor rather than an online supplier.

Testosterone replacement therapy uses pharmaceutical testosterone, delivered as a gel, cream, or injectable ester, to restore testosterone levels in men diagnosed with hypogonadism, a condition where the body genuinely does not produce enough testosterone on its own. These testosterone preparations are authorised, prescription-only medicines in Ireland with full HPRA marketing authorisation, meaning their manufacturing, labelling, and safety data have been formally reviewed by regulators.

Diagnosis matters here. A proper TRT work-up in Ireland involves confirmed low testosterone on at least two separate morning blood tests, alongside symptoms such as persistent fatigue, reduced libido, loss of muscle mass, or cognitive fog, plus a cardiac and prostate screening before treatment starts. This is not a lifestyle supplement decision; it is a medical diagnosis followed by a medical treatment, prescribed either through a specialist endocrinology service via the HSE or through a private men's health clinic.

Once started, TRT requires ongoing blood monitoring, typically covering total and free testosterone, haematocrit, oestradiol, and prostate-specific antigen, because testosterone therapy carries real risks if left unmonitored, including elevated red blood cell counts and effects on fertility. This monitoring burden is a genuine part of what you are paying for and what distinguishes a properly run TRT programme from simply buying testosterone and injecting it yourself.

The peptides most commonly discussed alongside TRT in Irish clinics and online forums include BPC-157, a synthetic peptide derived from a protective protein found in gastric juice and marketed for gut and soft-tissue healing; CJC-1295 and Ipamorelin, growth hormone-releasing peptides marketed to stimulate the body's own growth hormone output; and Thymosin Alpha-1, discussed for immune support. None of these has a marketing authorisation from the HPRA or the European Medicines Agency for use in Ireland or the wider EU.

This is an important distinction from TRT. Section 541 of the 2007 Irish medicines regulations prohibits advertising or promoting any human medicine that is not authorised or registered in Ireland, and the HPRA actively enforces this by ordering promotional content removed and by detaining illegally imported peptide products at ports and airports. A doctor may, in specific circumstances, prescribe an unauthorised medicine on a named-patient basis with documented clinical justification, under the framework set out in the Medical Council's Guide to Professional Conduct and Ethics, but this is a considered clinical decision rather than a routine retail transaction, and it looks nothing like ordering a vial online.

Because these substances have no marketing authorisation in Ireland, Gerovia does not publish price ranges, dosing information, or sourcing guidance for them here, in line with the advertising restrictions that apply to unauthorised medicines. If you are considering peptide therapy, the right first step is a consultation with a doctor who can discuss whether a named-patient prescription is clinically appropriate for you, not a search for the cheapest online supplier.

TRT's evidence base, built over several decades, is considerably deeper than that of the growth-hormone peptides. A 2026 systematic review and meta-analysis, pooling eleven studies and 1,512 men with diagnosed hypogonadism, compared TRT directly against clomiphene citrate, an alternative that tries to raise testosterone by stimulating the body's own production rather than replacing it. The review found no significant difference in how much serum testosterone rose between the two approaches overall, though injectable testosterone specifically achieved higher testosterone levels than clomiphene in one included study, and TRT was associated with a clearer improvement in libido scores than clomiphene across three studies covering 199 men.

That same review is a useful illustration of a genuine trade-off with TRT: because exogenous testosterone suppresses the body's own signalling to the testes, it can also suppress sperm production, which is why clomiphene and similar approaches are sometimes preferred in men who want to preserve fertility while treating symptoms of low testosterone. This is one randomised evidence base among several supporting TRT for diagnosed hypogonadism, and it is genuinely establishing, one randomised comparison found here, rather than an isolated positive result.

Critically, TRT is not being proposed as a general anti-ageing or performance intervention in this evidence base. It is a treatment for a diagnosed hormonal deficiency, and its evidence is strongest exactly where it is licensed: restoring measurable low testosterone towards a normal range and resolving the symptoms that come with genuine deficiency.

The evidence picture for BPC-157, CJC-1295, and Ipamorelin looks very different. Most of what is known about BPC-157's effects on tissue repair comes from animal studies. In rat models, BPC-157 has been shown to accelerate healing of tendons, ligaments, and gut tissue; there are no completed human clinical trials establishing that the same effects occur in people at any specific dose. Mechanistic plausibility, meaning a biologically sensible reason a substance might work, is not the same thing as a demonstrated benefit in a person, and the gap between promising animal data and confirmed human benefit is exactly where a great deal of the enthusiasm around these peptides currently sits.

CJC-1295 and Ipamorelin are growth hormone secretagogues, and there is reasonable pharmacological evidence that they do increase growth hormone and IGF-1 secretion in humans, since this mechanism has been studied in small clinical pharmacology trials. What is far less established is whether that increase translates into the broader anti-ageing, body-composition, or recovery benefits often claimed for these peptides in wellness marketing; robust, independently replicated randomised trials measuring those downstream outcomes in healthy adults are not part of the current evidence base.

Thymosin Alpha-1 has a longer history of use for immune support in some other countries for specific licensed indications, but it is not authorised for general immune support use in Ireland, and evidence for that broader wellness application in healthy adults is limited. Across this whole peptide category, the honest summary is thin human evidence, promising mechanistic and animal signals, and a regulatory position that keeps it firmly in the doctor-supervised, named-patient category rather than an over-the-counter or retail one.

TRT in Ireland has a fairly predictable cost structure. Private clinics typically charge €150 to €350 a month for ongoing monitoring and prescribing, with medication purchased separately at pharmacy prices, bringing a realistic total monthly outlay to somewhere between €200 and €450 depending on your specific protocol and provider (prices last checked September 2026). Initial consultations, including comprehensive bloods and a cardiac screen, commonly run around €349, with routine follow-ups closer to €149. The HSE route is significantly cheaper for those who qualify, particularly medical card holders whose medication may be covered, though specialist waiting times can run from six to eighteen months.

For the peptides discussed here, Gerovia does not publish price or dosing figures, in keeping with the advertising restrictions that apply to medicines with no marketing authorisation in Ireland. Costs vary considerably by clinic, by which specific peptides are involved, and by protocol length, and the only reliable way to get an honest figure is to ask a prescribing doctor directly during a consultation, where the conversation should also cover why a named-patient prescription is or is not clinically justified in your case.

This asymmetry is not an oversight. It reflects a genuine difference in regulatory status between an authorised medicine with a transparent, published price list and unauthorised medicines where publishing prices and doses publicly would itself constitute the kind of promotional content the HPRA is legally required to act on.

Anyone who competes in a sport with anti-doping testing needs to know that several of these substances carry serious consequences beyond the general legal picture. CJC-1295, Ipamorelin, and BPC-157 all appear on the World Anti-Doping Agency prohibited list, meaning a positive test can end a competitive career regardless of whether the substance was obtained through a doctor or otherwise. TRT itself is also prohibited in competitive sport without a valid therapeutic use exemption, since exogenous testosterone is one of the most heavily monitored substances in doping control.

This is worth raising explicitly because a meaningful share of people researching both TRT and peptide therapy are training seriously, and the assumption that a doctor's prescription automatically clears you for competition is a common and costly misunderstanding. If competitive sport is part of your life, have this conversation with both your prescriber and your sport's anti-doping authority before starting either therapy, not after a test result comes back.

Outside of competitive sport, the core legal distinction stands: TRT is a licensed medicine you can be lawfully prescribed and dispensed through the normal Irish pharmacy system, while the peptides discussed here sit in the more restricted named-patient prescribing category, with no lawful route to buying them as a consumer product regardless of how they are marketed online.

If you suspect low testosterone, the sensible starting point is not a peptide protocol or a TRT programme, but bloodwork. Persistent fatigue, low libido, and reduced muscle mass have overlapping causes, including thyroid problems, sleep disorders, depression, and simple deconditioning, several of which are more common than genuine hypogonadism and are treated very differently. A GP or endocrinologist can order the relevant morning testosterone tests and rule these alternatives in or out before any hormone-based treatment is considered.

If low testosterone is confirmed, TRT has the deeper evidence base, the clearer regulatory status, and the more predictable cost, which is why it remains the default, guideline-supported treatment for diagnosed hypogonadism in Ireland and across the EU. Peptide therapy may still come up in that same consultation, particularly for specific goals like soft-tissue recovery, but it belongs in a conversation about named-patient prescribing with a doctor who can weigh the thin human evidence against your specific situation, not in a shopping decision made from a wellness forum.

The honest bottom line is that these are not really competing options for the same problem. TRT treats a diagnosed hormone deficiency with an authorised medicine and a real evidence base. Peptide therapy, for now, remains an area of genuine scientific interest with far less human evidence and a regulatory status that keeps it appropriately cautious. Both deserve a proper medical conversation, and neither belongs in a routine you build for yourself from online research alone.